Core Viewpoint - The article highlights the recent A+ round financing of "Liuyedao," a medical surgical robot developer, which raised several million yuan to enhance its product development and global commercialization efforts [1]. Company Overview - Liuyedao (Shenzhen Liuyedao Robot Co., Ltd.) specializes in providing comprehensive AI surgical robot solutions for medical institutions, with a product range covering key clinical areas such as joint replacement, spinal trauma, oral implantation, neurosurgery, and vascular intervention [1][3]. - The founding team, led by Huang Zhijun, has a strong background in engineering and clinical medicine, with members from prestigious institutions and experience in notable companies like Siemens Medical and Hikvision [3]. Product Development - Liuyedao focuses on the independent development of surgical robots for spinal/trauma, joint replacement, oral implantation, and vascular intervention, with key products including hip-knee integrated joint replacement robots and oral implantation navigation robots [3]. - The company has achieved 100% localization of core components and has filed nearly 400 intellectual property applications, including 166 invention patents, breaking the technical monopoly of imported surgical robots [3]. Market Demand and Growth Potential - The Dencore® oral implantation navigation robot, designed with real-time tracking and precise positioning capabilities, has received regulatory approval and is expected to capture significant market share in the growing oral health sector [5]. - The RobPath® hip joint replacement navigation system offers intelligent surgical planning and high-precision positioning, having received dual certification from both China's NMPA and the US FDA [7]. Current Usage and Future Plans - Liuyedao's surgical robots are already in use in various hospitals, including grassroots and private specialty hospitals, indicating a broadening customer base [8]. - The company plans to accelerate the registration and market launch of multiple domestic surgical robots, aiming to expand its global footprint in the medical robotics sector [8].

Core Insights - The article highlights the successful A+ round financing of Shenzhen Liuye Knife Robot Co., Ltd., which raised several tens of millions of yuan to enhance its position in the domestic surgical robot market [1][4] - The company has achieved comprehensive localization of surgical robots through independent research and development, making its products widely used in various hospitals, including grassroots and private specialty hospitals [4][11] - Liuye Knife Robot is one of the first Chinese surgical robot manufacturers to obtain FDA registration, actively expanding its overseas market presence with over 20 overseas order contracts [4][11] Company Overview - Liuye Knife Robot was established in 2018 and focuses on multiple surgical fields, including joint replacement, spinal surgery, oral implantation, neurosurgery, and vascular intervention [11] - The company has built a comprehensive product line of surgical robots, supported by a strong R&D team with backgrounds in engineering and clinical medicine [11] Product Development - The company has developed the Robpath AI hip replacement surgical robot system, which features advanced capabilities such as automatic identification and segmentation of oral tissues, intelligent surgical planning, and real-time adjustments during surgery [5][9][10] - The surgical robots are designed to enhance the efficiency and precision of operations, with capabilities such as sub-millimeter accuracy and dynamic calibration of implant positions [10][12] Upcoming Events - The article mentions several upcoming global medical technology conferences, including the first Global Aesthetic Technology Conference in June 2025 and the third Global Surgical Robot Conference in September 2025 [1][12]